Anagrelide是咪唑(2,1-b)喹唑啉-2-1系列化合物之一,有很强的抗血小板凝聚作用。在人体研究中小剂量anagrelide引起了血小板减少。因此我们对此药治疗血小板增多症进行了评价。迄今为止,17名原发性血小板增多症患者中15人,2名真性红细胞增多和血小板增多患者以及1名慢性粒细胞性白血病和血小板增多症患者的血小板水平因此药治疗得到很好控制. Anagrelide is one of the imidazole (2,1-b) quinazoline-2-1 series compounds and has a strong anti-platelet aggregation effect. Small doses of anagrelide cause thrombocytopenia in human studies. Therefore, we evaluated the drug for treating thrombocytosis. To date, platelet levels in 15 of 17 patients with essential hyper thrombocytopenia, 2 patients with polycythemia vera and thrombocytosis and 1 with chronic myeloid leukemia and thrombocythemia have therefore been well controlled by this drug.